PTC Therapeutics Beats Q2 Estimates; Veracyte Posts 15% Revenue Surge, Raises FY26 Guidance

SentiSense · Published · Updated

PTC Therapeutics reported Q2 earnings that beat estimates. Veracyte also performed well, posting a 15% revenue surge and increasing fiscal year 2026 g...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis